Veronica Jimenez has a degree in Biotechnology and a PhD in Biochemistry and Molecular Biology from the Universitat Autònoma de Barcelona (UAB). Her scientific work centers on the pathophysiology of type 1 and type 2 diabetes, obesity, and metabolic-associated liver diseases (MASLD/MASH), as well as the development of innovative gene therapy approaches for these conditions. Dr. Jimenez's research utilizes transgenic animal models and advanced genetic engineering techniques targeting key metabolic tissues—such as the pancreas, liver, skeletal muscle, and adipose tissues—primarily through adeno-associated viral (AAV). Her expertise extends to gene therapy development for monogenic diabetes, pulmonary fibrosis, myocardial infarction, neurodegenerative diseases, and lysosomal storage disorders affecting muscle and bone. Dr. Jimenez is recognized for her proficiency in AAV-mediated genetic engineering across various tissues and animal models, which has led to significant national and international collaborations. She has published 30 Q1 research articles, 1 review and 3 book chapters, holds 12 patents (10 licensed to industry), and co-founded two gene therapy spin-offs. Since 2024, she is a Lecturer in Biochemistry and Molecular Biology at UAB.